Influence of PDZK1 on lipoprotein metabolism and atherosclerosis

Olivier Kocher1, Ayce Yesilaltay, Ching-Hung Shen

  • 1Department of Pathology, Beth Israel-Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA. okocher@bidmc.harvard.edu

Insights

Scaffold protein PDZK1 is crucial for HDL receptor SR-BI expression. PDZK1 deficiency promotes atherosclerosis in mice by disrupting lipoprotein metabolism, highlighting its role in cardiovascular disease prevention.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cardiovascular Research

Background:

  • PDZK1 is a scaffold protein that interacts with membrane proteins, including the HDL receptor SR-BI.
  • SR-BI expression and activity show a tissue-specific dependence on PDZK1.
  • PDZK1 knockout mice exhibit reduced hepatic SR-BI expression and dyslipidemia.

Purpose of the Study:

  • To investigate the role of PDZK1 in atherosclerosis development.
  • To determine the impact of PDZK1 deficiency on SR-BI expression and lipoprotein metabolism in vivo.
  • To assess the contribution of PDZK1 to cardiovascular disease pathogenesis.

Main Methods:

  • Utilized PDZK1 knockout (KO) mice and apolipoprotein E (apoE) KO mice.
  • Generated PDZK1/apoE double knockout mice.
  • Administered a high-fat/high-cholesterol diet to study atherosclerosis progression.
  • Quantified SR-BI protein expression in various tissues.

Main Results:

  • PDZK1 deficiency significantly reduced hepatic SR-BI protein levels (approx. 95%).
  • PDZK1 KO mice displayed dyslipidemia with elevated plasma cholesterol and large HDL particles.
  • PDZK1/apoE double KO mice developed aortic root atherosclerosis but not occlusive coronary artery disease or myocardial infarction, unlike SR-BI/apoE double KO mice.
  • Residual SR-BI expression in PDZK1-deficient mice likely mitigated severe cardiovascular events.

Conclusions:

  • PDZK1 is essential for maintaining normal SR-BI expression and function.
  • PDZK1 deficiency promotes atherosclerosis by impairing lipoprotein metabolism.
  • PDZK1 plays a critical role in preventing cardiovascular disease.

Related Concept Videos

Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...